Yes ASMB data questioning ability of DAAs to achieve a functional cure PS for those not following ENTA closely they are working on a novel MOA in HBV w the goal of a 3 drug oral cocktail. It’s a long shot but if it works the opportunity is larger than HCV. It’s the kind of opportunity I think a large pharma would take a flier on before final results are in
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.